Cecilia Bull1, Wahab A Syed, Sabrina C Minter, M Scott Bowers. 1. Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Abstract
BACKGROUND: Prefrontal cortex (PFC) dysfunction is believed to contribute to the transition from controlled substance use to abuse. Because astrocytes have been suggested to play a key role in the development and maintenance of drug-seeking behaviors, we sought to determine whether PFC astrocytes are affected by ethanol (EtOH) self-administration. METHODS: EtOH consumption was modeled in rats by 3 self-administration paradigms where EtOH was made concurrently available with water in the home cage either continuously (CEA) or intermittently (IEA). In the third paradigm, EtOH was only available in the operant chamber (OEA). To avoid the potential confound of acute EtOH effects, all rats were sacrificed after either 24-hour or 3-week abstinence. In all groups, the effect of EtOH consumption on PFC astrocytes was measured using unbiased stereological counting of cells expressing the astrocyte marker glial fibrillary acidic protein (GFAP). GFAP immunoreactivity commonly changes in response to pharmacological insult or injury. RESULTS: GFAP-positive astrocyte number increased in the prelimbic and anterior cingulate cortex regions of the PFC after IEA. No change was found in the infralimbic or orbitofrontal cortex after IEA. After 3-week abstinence, there was a reduction of astrocytes in the prelimbic and orbitofrontal cortex of the CEA cohort as well as a reduction in the orbitofrontal cortex of the OEA cohort. CONCLUSIONS: These findings demonstrate that discrete PFC subregions contain GFAP-positive astrocyte populations that respond differentially to distinct EtOH consumption paradigms. A better understanding of how specific astrocyte populations uniquely adapt to EtOH consumption could provide insight for targeted therapeutic interventions.
BACKGROUND: Prefrontal cortex (PFC) dysfunction is believed to contribute to the transition from controlled substance use to abuse. Because astrocytes have been suggested to play a key role in the development and maintenance of drug-seeking behaviors, we sought to determine whether PFC astrocytes are affected by ethanol (EtOH) self-administration. METHODS:EtOH consumption was modeled in rats by 3 self-administration paradigms where EtOH was made concurrently available with water in the home cage either continuously (CEA) or intermittently (IEA). In the third paradigm, EtOH was only available in the operant chamber (OEA). To avoid the potential confound of acute EtOH effects, all rats were sacrificed after either 24-hour or 3-week abstinence. In all groups, the effect of EtOH consumption on PFC astrocytes was measured using unbiased stereological counting of cells expressing the astrocyte marker glial fibrillary acidic protein (GFAP). GFAP immunoreactivity commonly changes in response to pharmacological insult or injury. RESULTS:GFAP-positive astrocyte number increased in the prelimbic and anterior cingulate cortex regions of the PFC after IEA. No change was found in the infralimbic or orbitofrontal cortex after IEA. After 3-week abstinence, there was a reduction of astrocytes in the prelimbic and orbitofrontal cortex of the CEA cohort as well as a reduction in the orbitofrontal cortex of the OEA cohort. CONCLUSIONS: These findings demonstrate that discrete PFC subregions contain GFAP-positive astrocyte populations that respond differentially to distinct EtOH consumption paradigms. A better understanding of how specific astrocyte populations uniquely adapt to EtOH consumption could provide insight for targeted therapeutic interventions.
Authors: Jose J Miguel-Hidalgo; James C Overholser; Herbert Y Meltzer; Craig A Stockmeier; Grazyna Rajkowska Journal: Alcohol Clin Exp Res Date: 2006-11 Impact factor: 3.455
Authors: Sabine M Grüsser; Jana Wrase; Sabine Klein; Derik Hermann; Michael N Smolka; Matthias Ruf; Wolfgang Weber-Fahr; Herta Flor; Karl Mann; Dieter F Braus; Andreas Heinz Journal: Psychopharmacology (Berl) Date: 2004-09 Impact factor: 4.530
Authors: Sean P Farris; Brien P Riley; Robert W Williams; Megan K Mulligan; Michael F Miles; Marcelo F Lopez; Robert Hitzemann; Ovidiu D Iancu; Alexander Colville; Nicole A R Walter; Priscila Darakjian; Denesa L Oberbeck; James B Daunais; Christina L Zheng; Robert P Searles; Shannon K McWeeney; Kathleen A Grant; R Dayne Mayfield Journal: Alcohol Date: 2017-12-06 Impact factor: 2.405
Authors: Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield Journal: Pharmacogenomics Date: 2016-12-05 Impact factor: 2.533
Authors: Milky Kohno; Jeanne Link; Laura E Dennis; Holly McCready; Marilyn Huckans; William F Hoffman; Jennifer M Loftis Journal: Pharmacol Biochem Behav Date: 2019-01-26 Impact factor: 3.533
Authors: Michael D Scofield; Hao Li; Benjamin M Siemsen; Kati L Healey; Phuong K Tran; Nicholas Woronoff; Heather A Boger; Peter W Kalivas; Kathryn J Reissner Journal: Biol Psychiatry Date: 2015-12-31 Impact factor: 13.382
Authors: Mary-Louise Risher; Hannah G Sexton; W Christopher Risher; Wilkie A Wilson; Rebekah L Fleming; Roger D Madison; Scott D Moore; Cagla Eroglu; H Scott Swartzwelder Journal: Alcohol Clin Exp Res Date: 2015-11-05 Impact factor: 3.455
Authors: Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-10-06 Impact factor: 5.067